Burshtein Joshua, Shah Milaan, Zakria Danny, Lockshin Benjamin, Crowley Jeff, Merola Joseph F, Gordon Ken, Shahriari Mona, Korman Neil J, Chovatiya Raj, Kalb Robert, Lebwohl Mark
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
US Dermatology Partners, Rockville, MD, USA.
Dermatol Ther (Heidelb). 2024 Feb;14(2):323-339. doi: 10.1007/s13555-024-01099-y. Epub 2024 Feb 10.
Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab.
A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the use of bimekizumab for moderate to severe psoriasis and psoriatic arthritis. A panel of nine dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using Strength of Recommendation Taxonomy criteria.
The literature search produced 102 articles that met criteria. A thorough screening of the studies for relevance to the research question resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations, 12 of which were given a strength of "A", one of which was given a strength of "B", and one of which was given a strength of "C".
Bimekizumab results in rapid and long-lasting clinical improvement for patients with moderate to severe plaque psoriasis and psoriatic arthritis. It has demonstrated superior efficacy when compared to several other biologics. The safety profile is consistent with other biologics, except for an increased incidence of oropharyngeal candidiasis.
银屑病是一种慢性炎症性疾病，会影响皮肤、关节和其他几个器官系统，带来重大疾病负担。比美吉珠单抗是首个同时靶向白细胞介素（IL）-17A和白细胞介素-17F的单克隆抗体，已证明对治疗中度至重度银屑病有效。将这种药物纳入临床实践的指南有限。本研究的目的是让一组银屑病管理专家综合当前文献，并就比美吉珠单抗的使用提供共识声明和指导。
对PubMed、Scopus和谷歌学术进行了全面的文献检索，以查找关于比美吉珠单抗用于中度至重度银屑病和银屑病关节炎的英文原创研究文章。一组九位在银屑病治疗方面具有丰富专业知识的皮肤科医生聚集在一起，审查这些文章，并就这种新药达成共识声明。采用改良的德尔菲法批准每项声明，并使用推荐强度分类标准分配推荐强度。
文献检索产生了102篇符合标准的文章。对这些研究与研究问题的相关性进行全面筛选后，得到19篇文章。在圆桌讨论之前，将这些文章分发给所有小组成员进行审查。小组一致投票通过了14项共识声明和建议，其中12项被赋予“A”级强度，1项被赋予“B”级强度，1项被赋予“C”级强度。
比美吉珠单抗可使中度至重度斑块状银屑病和银屑病关节炎患者实现快速且持久的临床改善。与其他几种生物制剂相比，它已证明具有卓越的疗效。除了口咽念珠菌病的发病率增加外，其安全性与其他生物制剂一致。
